Kuros Biosciences Ag Stock Net Income
| CSBTF Stock | USD 38.34 0.00 0.00% |
Fundamental analysis of Kuros Biosciences allows traders to better anticipate movements in Kuros Biosciences' stock price by examining its financial health and performance throughout various phases of its business cycle.
Kuros |
Kuros Biosciences AG Company Net Income Analysis
Kuros Biosciences' Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Kuros Biosciences Net Income | (7.54 M) |
Most of Kuros Biosciences' fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kuros Biosciences AG is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, Kuros Biosciences AG reported net income of (7.54 Million). This is 102.21% lower than that of the Healthcare sector and 110.77% lower than that of the Biotechnology industry. The net income for all United States stocks is 101.32% higher than that of the company.
Kuros Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kuros Biosciences' direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kuros Biosciences could also be used in its relative valuation, which is a method of valuing Kuros Biosciences by comparing valuation metrics of similar companies.Kuros Biosciences is currently under evaluation in net income category among its peers.
Kuros Fundamentals
| Return On Equity | -0.14 | |||
| Return On Asset | -0.0667 | |||
| Profit Margin | (0.74) % | |||
| Operating Margin | (0.64) % | |||
| Current Valuation | 40.53 M | |||
| Shares Outstanding | 36.54 M | |||
| Shares Owned By Insiders | 35.33 % | |||
| Shares Owned By Institutions | 16.83 % | |||
| Price To Earning | 0.33 X | |||
| Price To Book | 0.79 X | |||
| Price To Sales | 4.63 X | |||
| Revenue | 13.81 M | |||
| Gross Profit | 10.07 M | |||
| EBITDA | (5.29 M) | |||
| Net Income | (7.54 M) | |||
| Cash And Equivalents | 28.62 M | |||
| Cash Per Share | 0.87 X | |||
| Total Debt | 2.21 M | |||
| Debt To Equity | 0.03 % | |||
| Current Ratio | 2.91 X | |||
| Book Value Per Share | 2.23 X | |||
| Cash Flow From Operations | (5.45 M) | |||
| Earnings Per Share | (0.24) X | |||
| Number Of Employees | 64 | |||
| Beta | 0.77 | |||
| Market Capitalization | 70.16 M | |||
| Total Asset | 91.34 M | |||
| Retained Earnings | (37 M) | |||
| Working Capital | 16 M | |||
| Current Asset | 18 M | |||
| Current Liabilities | 2 M | |||
| Z Score | 18.6 | |||
| Net Asset | 91.34 M |
About Kuros Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kuros Biosciences AG's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kuros Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kuros Biosciences AG based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Other Information on Investing in Kuros Pink Sheet
Kuros Biosciences financial ratios help investors to determine whether Kuros Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Kuros with respect to the benefits of owning Kuros Biosciences security.